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Abstract
Background: The relevance of persistent cognitive deficits to the pathogenesis and prognosis of
bipolar disorders (BD) is understudied, and its translation into clinical practice has been limited by
the absence of brief methods assessing cognitive status in Psychiatry. This investigation assessed the
psychometric properties of the Spanish version of the Screen for Cognitive Impairment in
Psychiatry (SCIP-S) for the detection of cognitive impairment in BD.
Methods: After short training, psychiatrists at 40 outpatient clinics administered the SCIP three
times over two weeks to a total of 76 consecutive type I BD admissions. Experienced psychologists
also administered a comprehensive battery of standard neuropsychological instruments to clinical
sample and 45 healthy control subjects.
Results: Feasibility was supported by a brief administration time (approximately 15 minutes) and
minimal scoring errors. The reliability of the SCIP was confirmed by good equivalence of forms,
acceptable stability (ICC range 0.59 to 0.87) and adequate internal consistency (Chronbach's alpha
of 0.74). Construct validity was granted by extraction of a single factor (accounting 52% of the
variance), acceptable correlations with conventional neuropsychological instruments, and a clear
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Health and Quality of Life Outcomes 2009, 7:28 http://www.hqlo.com/content/7/1/28differentiation between bipolar I and normal samples. Efficiency was also provided by the adequate
sensitivity and specificity.
Limitations: The sample size is not very large. The SCIP and the neurocognitive battery do not
cover all potentially relevant cognitive domains. Also, sensitivity to change remains unexplored.
Conclusion: With minimal training, physicians obtained a reliable and valid estimate of cognitive
impairment in approximately 15 minutes from an application of the SCIP to type I BD patients.
Background
Cognitive deficits in bipolar disorders are relevant to cere-
bral pathogenesis and prognosis, but they are often
neglected in routine clinical practice. The deficits persist
beyond the resolution of acute symptoms [1-3] and show
familial co-segregation [4] consistent with expectations
for a genetically based endophenotypic trait [5]. The cog-
nitive deficits in bipolar disorder are also directly related
to functional status or psychosocial outcomes [6,7], and
the severity of the cognitive impairment at initiation of
therapeutic intervention can be a powerful predictor of
functional recovery one year later [8]. Similar observa-
tions in schizophrenia [9] prompted the National Insti-
tutes of Health initiative for Measurement and Treatment
of Cognitive Impairment in Schizophrenia [10], and a
parallel initiative for bipolar disorder may be in order.
This would be facilitated by a more wide spread incorpo-
ration of cognitive assessments into the routine clinical
examinations of bipolar patients.
A relative paucity of routine cognitive assessments in cur-
rent clinical practice is apparent, however, and this may
relate to a perceived absence of feasible and valid methods
of quantification. For example, although the Repeatable
Battery for the Assessment of Neuropsychological Status
(RBANS) [11], and the Brief Assessment of Cognition in
Schizophrenia (BACS) [12], are useful tools for psychiat-
ric patients, they require relatively expensive test-adminis-
tration kits and at least 30 minutes for administration. In
contrast, the Mini-Mental State Examination (MMSE)
[13], a staple in the assessment of cognitive deficits asso-
ciated with neurological disorders, is completed on a sin-
gle printed page of paper in approximately 15 minutes.
Although the MMSE is sensitive to the severity of demen-
tia in geriatric samples, it has proven to be unstable and
unreliable in psychotic or affective disorders where it
underestimates the cognitive disturbance in younger sam-
ples and overestimates pathology in older, less educated,
or less intelligent samples [14-17].
The Screen for Cognitive Impairment for Psychiatry (SCIP)
[18] was developed to offer a brief tool for the quantifica-
tion of cognitive deficits in higher functioning psychiatric
patients. The SCIP consists of a single page with five sub-
tests of cognitive skill that can be completed with a pencil
and a timer. Each subtest requires two to three minutes, for
a total administration time of approximately 15 minutes.
The subtests within the SCIP quantify working memory,
immediate and delayed verbal list learning, verbal fluency,
and psychomotor speed, all of which may be impaired in
schizophrenia or bipolar disorders [3,19-22]. Three alter-
nate forms of the SCIP are available, with good reliability,
validity, and form equivalence [18]. A direct translation to
Spanish, with minor changes from the English variant, was
accomplished by two Spanish-born bilingual professionals,
one a Spanish philology graduate with extensive knowl-
edge of English, and the second a neuropsychologist with
expertise in the scale contents. A back translation was
deemed an adequate representation of the original English
version after it was created by a native English-speaking
bilingual language school teacher from the University of
Barcelona, who also possessed a degree in psychology. The
three alternate forms of the Spanish-language SCIP (SCIP-
S) demonstrated equivalence, reliability, and validity in a
University-recruited normal control sample [23]; the sensi-
tivity, reliability, and validity of the SCIP-S was recently
confirmed in a large sample of patients suffering from
schizophrenia [24]. The present investigation was designed
to assess the sensitivity, reliability and validity of the SCIP
for detection and quantification of cognitive impairment in
euthymic patients suffering from a type I bipolar disorder.
Method
Sample
Participants included a sample of 76 bipolar I patients
and a sample of 45 matched healthy controls, all of whom
provided written consent after full disclosure of the study
methods. The clinical sample was recruited through 40
outpatient psychiatric clinics across Spain, so the sample
selection had a nested structure. They were 18 to 55 years
of age with a type I bipolar disorder diagnosed by an expe-
rienced psychiatrist according to DSM IV-TR criteria [25].
They were in a stable phase of the illness defined by at
least 6 months in remission, a Hamilton Depression Scale
(HAMD) [26] score less than 8, a Young Mania Rating
Scale (YMRS) [27] score less than 6, and no required
changes in the type or dose of psychopharmacological
treatment for the duration of the study. Subjects with
severe or unstable medical or neurological problems, illit-
erate, other primary psychiatric disorders including major
depression, or ongoing participation in a clinical trial
were excluded. The control sample was statisticallyPage 2 of 10
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tional level, and they were free of significant symptoms of
psychiatric illness assessed with the interview Compre-
hensive Assessment of Symptoms and History (CASH)
[28]. Controls were excluded if they had severe medical or
neurological problems, met criteria for a psychiatric disor-
der, were participating in a clinical trial, were illiterate, or
having any first degree relative with mental illness.
Procedure
The method was reviewed and approved by the Ethics
Committee of the University of Barcelona. The bipolar
sample participated in three test sessions, denoted below
as Visits 1 (V1), 2 (V2), and 3 (V3), whereas the control
sample participated in only one test session at V1. The
baseline V1 session for all subjects consisted of an inter-
view to obtain sociodemographic background, a SCIP
examination, and approximately 1.5 hours of testing with
conventional standardized neuropsychological instru-
ments (NPS). The CASH was also completed with the con-
trol subjects at V1. The SCIP was administered by one of
44 psychiatrists, and the NPS examination was adminis-
tered by one of 41 neuropsychologists. The psychiatrists
participated in a one hour SCIP training session provided
by a neuropsychologist with extensive experience in cog-
nitive assessment and four years' experience with the
SCIP. The baseline (V1) NPS examination consisted of the
Edinburgh Handedness Inventory [29], the Wechsler
Adult Intelligence Scale-III (WAIS-III) [30], Vocabulary,
Symbol Search, Digit-Symbol Coding, Arithmetic, Digit
Span, and Letter-Number Sequencing Subtests, as well as
the Wechsler Memory Scale-III (WMS-III) [31], Wordlist I
and Wordlist II Subtests, the Wisconsin Card Sorting Test
(WCST) [32], the Trail Making Test (TMT- A-B) [33] the
Semantic Fluency Test [34,35]. The bipolar sample also
participated in a clinical assessment at baseline (V1) that
was repeated seven (V2) and fourteen (V3) days later and
included ratings on the YMRS, the HAMD, the Clinical
Global Impression inventory (CGI-G) [36], the Social and
Occupational Functioning Assessment Schedule (SOFAS-
EEASL) [37], and the SCIP. Participants were randomly
assigned to receive one of six combinations of SCIP form
orders constructed from a complete counterbalance of
alternate forms between V1 and V2 to assess practice
effects, followed by a repetition of the V2 form at V3 to
assess common form stability (i.e., forms 1-2-2, 1-3-3, 2-
1-1, 2-3-3, 3-1-1, 3-2-2). Additional details of the instru-
mentation for quantification of history, psychosocial sta-
tus, and clinical symptoms, as well as the measures
applied in the standardized NPS screen are widely refer-
enced and available in their respective manuals.
Each of the three alternate forms of the SCIP [18] contains
an equivalent Verbal Learning Test with Immediate Recall
(VLT-I), a Working Memory Test (WMT), a Verbal Fluency
Test (VFT), a Verbal Learning Test with Delayed Recall
(VLT-D), and a Processing Speed Test (PST). The VLT-I is
a variant of the Rey Auditory Verbal List Learning Test
(RAVLT) [38] consisting of three trials of a 10 word list-
learning task with immediate recall after each spoken
presentation of the list. The primary dependent variable is
the sum of the number of words correctly recalled over the
three trials. The WMT is a variant of the Brown-Peterson
Consonant Trigram Test (CTT) [39,40], consisting of eight
3-letter combinations of consonants, with two trigrams
each assigned to a 0, 3, 9, or 18 second delay with back-
ward counting distraction. The primary dependent varia-
ble is the sum of the letters correctly recalled. The VFT is a
variant of the Controlled Oral Word Association Test
(COWAT) [41] consisting of two trials of 30 seconds dur-
ing which the subject is invited to generate words that
begin with a given letter of the alphabet while avoiding
numbers, proprietary names, or a single root with multi-
ple suffixes. The dependent variable is the sum of accept-
able words over the two trials. The VLT-D consists of a
delayed recall test of the VLT-I words. The PST is an origi-
nal visuomotor tracking task that requires the subject to
translate the Morse code equivalents of six letters from the
alphabet in boxes under a randomly distributed sequence
of the letters. The dependent variable consists of the
number of correct sequential translations in 30 seconds.
Statistical analysis
The feasibility of the SCIP was examined in relation to the
scoring and correction errors, patient tolerance of the pro-
cedures, and the time required to complete the SCIP.
The reliability of the SCIP was assessed by examination of
alternate form equivalence, the test-retest reliability, the
internal consistency within the bipolar sample, and the
magnitude of practice effects observed with alternate
forms. The alternate form equivalence was measured by
means of a multivariate and univariate analysis of vari-
ance of baseline subtest and total scores, respectively. Test-
retest reliability was assessed with intra-class correlation
coefficients (ICC) between the first and second adminis-
trations of common forms (i.e. V2/V3). Consistency was
examined using Cronbach's alpha coefficient applied to
the three SCIP administrations. Reliability was also
assessed by multivariate (subscale scores) and univariate
(total score) analysis of practice effects at baseline (V1)
and V2; the magnitude of these practice effects was calcu-
lated with Cohen's d, representing the difference between
mean scores at V2 and baseline divided by the standard
deviation of the baseline visit.
The validity of the SCIP for a quantification of cognitive
impairment in bipolar disorder was examined with an
assessment of construct and convergent validity, and scale
sensitivity and specificity. Construct validity was examined
by principal components factor analysis of the SCIP sub-
scale scores. Correlations between subtests were evaluatedPage 3 of 10
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between total SCIP score and neuropsychological battery
were also explored by means of Pearson correlation coeffi-
cient. The validity of the SCIP in the differentiation
between the bipolars and matched healthy control sample
was assessed by multivariate and univariate comparison of
the baseline SCIP subscale scores and total score, respec-
tively. The magnitude of these differences on each subscale
score, and the total score, was calculated with Cohen's d,
representing the difference between the baseline mean
scores of controls and patients divided by the pooled stand-
ard deviation. Also, the ability of the SCIP to distinguish
between patients who had cognitive impairment and those
who did not, was assessed carrying out a sensitivity and spe-
cificity analysis of the SCIP total score in the framework of
logistic regression and receiver operating curve (ROC) anal-
ysis. The criterion to establish the differentiation between
cognitive impairment and non-cognitive impairment in the
bipolar sample was based on a global weighted z score of
the neuropsychological battery (excluding the SCIP) after
standardization using the baseline control group. Several
studies have confirmed that cognitive impairment severity
in patients with bipolar disorder is about 0.5 to 1.5 stand-
ard deviations lower than the healthy population [42,43];
consequently as a general criterion the cut off score was
established at ≤ -1 standard deviation.
The SPSS version 12.0 statistical software was used with
significance levels of 0.01 for Pearson correlations and
0.05 in all other cases.
Results
1. Sample descriptive statistics
The bipolar I sample consisted of 76 patients with a mean
duration of illness of 146.88 (SD = 96.96) months. They had
experienced an average of 4.38 (SD = 3.35) manic episodes,
4.33 (SD = 4.47) depressive episodes, and 3.31 (SD = 4.31)
hospital admissions. Comorbid disorders were apparent in
two patients (2.63%) included in the present bipolar I sam-
ple and included one patient with obsessive compulsive fea-
tures and another with anxiety features. At the time of
cognitive assessment, patients were on lithium (N = 22;
28.85%), lithium plus one antipsychotic (N = 31; 40.79%),
lithium plus two antipsychotics (N = 3; 3.95%), one antipsy-
chotic medication (N = 12; 15.79%), two antipsychotics (N
= 2; 2.63%) or three antipsychotics (N = 1; 1.32%). Five
patients were free of lithium and antipsychotics. Some
patients (N = 52; 68.42%) were additionally taking another
drug treatment (e.g. antidepressants, benzodiazepines). All
patients were maintained on their baseline medications
without modifications of dose through the course of this
investigation. Caffeine was consumed within 24 hours prior
to testing by 52.6% of the sample, nicotine by 53.9%, and
alcohol by 1.3%. The principal sociodemographic variables
of the study sample are reported in Table 1. On the baseline
examination, the bipolar group received average SOFAS rat-
ings at of 76.81 (SD = 14.27), midway between "some diffi-
culty" and "good functioning".
The control group was composed of 25 males and 20
females with a mean age of 37.69 (SD = 8.20) ranging
from 20 to 54 years old. Regarding their education level,
31.10% followed primary education, 40.00% secondary
education and 28.90% had university education. No sig-
nificant differences were observed between the patient
and control groups in gender (χ2(1) = 1.324; p = 0.250),
education (χ2(4) = 2.03; p = 0.730), or age (t(119) = 1.597;
p = 0.113).
2. Feasibility
The relatively brief training session for the SCIP adminis-
tration resulted in a mean kappa index of agreement in
Table 1: Demographic characteristics of the study sample.
Variable N % Variable N %
Sex Cohabitation
Male 34 44.7 Family of origin 30 39.5
Female 42 55.3 Own family 35 46.1
Marital status Friends 0 0
Single 35 46.1 Tutelage home 0 0
Married 25 32.9 Alone 9 11.8
Living as couple 6 7.9 Others 2 2.6
Widowed 1 1.3 Occupational status
Separated/divorced 9 11.8 Student 2 2.6
Educational level Employee 21 27.6
Illiterate 0 0.0 Liberal professional 8 10.5
Functionally illiterate 1 1.3 Non-remunerated work 1 1.3
Primary 28 36.8 Disabled 20 26.3
Secondary 24 31.6 Unemployed 8 10.5
University studies 22 28.9 Retired 8 10.5
Others 1 1.3 Housewife 8 10.5
Age Mean (SD) 76 40.30 (8.98)Page 4 of 10
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ated well by both bipolar patients and normal controls, as
apparent in the successful completion of a complete base-
line SCIP in all 76 bipolar patients and 45 controls. Sev-
enty-four patients (97.37%) reported to all three
programmed visits. One bipolar subject completed the
SCIP at all three sessions but refused to complete some of
the baseline NPS tests. Two bipolar subjects did not return
for the third session and gave no explanation for their dis-
continuation. The average time to complete each of the
first two SCIP assessments in the bipolar sample was
15.61 (SD = 5.01) and 14.16 (SD = 4.92) minutes.
3. Reliability
The equivalence of the three alternate forms of the SCIP
was supported by the absence of significant differences
between forms in a multivariate analysis of variance com-
paring the baseline scores of the bipolar sample, (F(10,140)
= 0.813, p = 0.616) (see Table 2). Univariate comparisons
also revealed no significant differences between the alter-
nate subtests of the SCIP (all p > 0.05).
Good test-retest reliability was also apparent in the intra-
class correlation coefficients (ICC) between the first and
second administrations of common forms (i.e. V2/V3),
with values ranging from a low of 0.59 for the VLT-D and
a high of 0.82 for the PST (see Table 3). The sum of the
subscale scores achieved an ICC of 0.87.
The SCIP subtests exhibited adequate internal consist-
ency, with Chronbach's alphas of 0.74, 0.78, and 0.77 at
Visits 1, 2 and 3, respectively.
The multivariate analysis of variance suggested the
absence of a general practice effect between alternate
forms administered at baseline (V1) and one week later
(V2) (F(5,70) = 2.20, p = 0.064), but univariate comparison
between V1 and V2 for total SCIP score revealed signifi-
cant differences (see Table 4). This contrasts with the mul-
tivariate comparison between common forms
administered at V2 and one week later (V3) (F(5,69) =
13.47, p < 0.05), resulting from significant improvements
on the second administration of all subscales (p < 0.05)
except the WMT (t(73) = 1.23, p = 0.221) and the VFT (t(73)
= 1.95, p = 0.055).
4. Validity evidences
The construct validity of the SCIP as a measure of cogni-
tive impairment in bipolar disorder was supported by the
principal component factor analysis extraction of a single
factor with an eigenvalue of 2.610 accounting for 52.21%
of total variance, and the high loading of each of the five
subtests on this factor, ranging from 0.53 for the PST to
0.81 for VLT-D. Moreover, the analysis of internal consist-
ency by means of the Cronbach's alpha coefficient
showed that removal of any subtest would involve a
decrease in this coefficient, which supports the relevance
of each of them. The correlations between SCIP subtests'
scores are shown in table 5; they range from 0.18 (VLT-I –
PST) to 0.68 (VLT-I – VLT-D).
Pearson's correlation coefficient between the SCIP total
score and the global weighted z score from the neuropsy-
chological battery abovementioned was 0.74 (p < 0.01),
suggesting that the SCIP provides valid measure of global
cognitive impairment in bipolar disorder. A significant
correlation was also observed between SCIP total score
and the SOFAS (r = 0.45, p < 0.01).
In relation to differentiation between patients and con-
trols, the multivariate analysis revealed a significant differ-
ence between groups (F(5,115) = 11.28, p < 0.05), with
the healthy controls exceeding the performance of the
bipolar group on all five SCIP subtests (all p < 0.05), with
Cohen d effect sizes ranging from a medium on the two
VLT and WMT subtests to a high on the other subtests (see
Table 6). The univariate comparison of the total SCIP
score also revealed a high effect size (d = 1.16).
Moreover, in order to assess the ability of the SCIP to dis-
tinguish between patients who had cognitive impairment
and those who did not, logistic regression analysis was
Table 2: Mean SCIP scores for each of the parallel forms.
Form 1 Form 2 Form 3
Subtest N Mean (SD) N Mean (SD) N Mean (SD) Significance
VLT-I 25 19.08 (4.50) 24 20.50 (4.72) 27 18.70 (3.85) F(2,73) = 1.179 p = 0.313
WMT 25 17.16 (3.64) 24 17.71 (3.99) 27 17.04 (4.11) F(2,73) = 0.206 p = 0.814
VFT 25 14.64 (5.31) 24 15.96 (5.87) 27 12.85 (4.50) F(2,73) = 2.272 p = 0.110
VLT-D 25 5.36 (2.69) 24 5.54 (2.60) 27 4.93 (2.00) F(2,73) = 0.435 p = 0.649
PST 25 9.44 (2.22) 24 8.75 (2.74) 27 9.11 (3.18) F(2,73) = 0.385 p = 0.682
Total SCIP 25 65.68 (13.71) 24 68.46 (13.92) 27 62.63 (13.65) F(2,73) = 1.167 p = 0.317
VLT-I = Verbal Learning Test-Immediate; WMT = Working Memory Test; VFT = Verbal Fluency Test; VLT-D = Verbal Learning Test-Delayed; PST 
= Processing Speed Test; Total SCIP = SCIP total scorePage 5 of 10
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as a classification variable, presenting a global percentage
of correct classifications of 74.28%, a Nagelkerke R2 of
0.453, and the Hosmer-Lemeshow statistics was no signif-
icant. The ROC analysis obtained an area under the curve
of 0.837 (p < 0.05) (see Figure 1). The most balanced cut-
off point was established at ≤ 67, presenting a sensitivity
of 73.53%, and a specificity of 72.22%.
Discussion
The well documented cognitive limitations associated with
bipolar disorders [3,19] are recognized by the patients [44],
have characteristics of an illness endophenotype [4], and
directly relate to functional or psychosocial recovery after
the onset of illness [6,8,45]. Despite the apparent relevance
of cognitive impairment to diagnosis, pathogenesis, and
prognosis, this aspect of the illness is often neglected in
both clinical practice and epidemiological studies [46]. The
neglect may relate to the lack of brief standardized instru-
ments with proven validity for the detection and quantifi-
cation of the cognitive limitations associated to bipolar
disorders. The SCIP [18] was developed to address several
limitations of similar tools, and the current prospective
evaluation provides the first demonstration supporting the
feasibility, reliability, and validity of the Spanish version of
the SCIP (SCIP-S) in a bipolar sample. The feasibility of the
SCIP-S for routine clinical practice was supported by mini-
mal errors of implementation or scoring committed by psy-
chiatrists after a relatively brief one hour training session, a
brief administration time of approximately 15 minutes per
patient, and the minimal instrument requirements (paper,
pencil, and clock). Tolerability was also demonstrated.
In addition to feasibility and tolerability, the current
investigation supported the reliability and the validity of
the SCIP applied to bipolar disorder. The three alternate
forms of the SCIP-S produced equivalent baseline scores
on all five subtests, and the overall intra-class coefficient
was high. Very similar reliability results have been
reported in normal college student samples for both the
original English SCIP [18] and the Spanish SCIP [24]. The
construct validity of the SCIP for detection of cognitive
impairment in bipolar disorder was supported by the
extraction of a single significant factor, namely cognitive
impairment, and the high correlation between the neu-
ropsychological battery and the overall factor score. Simi-
lar results were encountered with a larger schizophrenic
sample, where the scores also converged on a single cog-
nitive factor accounting for almost 50% of the total vari-
ance [24]. The SCIP general score was also correlated with
functional status, as anticipated from prior studies with
more prolonged cognitive batteries. As confirmed by sen-
sitivity and specificity analysis, and taking into account
that the SCIP is a screening test, the SCIP total score is an
acceptable measure for distinguishing between patients
with and without cognitive impairment.
In sum, the SCIP produced a valid quantification of cog-
nitive status in bipolar patients by psychiatrists with min-
imal training on the tool, and the small magnitude of
practice effects with the alternate forms suggest that it may
also be useful for monitoring progress through time.
Table 3: SCIP Intra-Class Correlation Coefficients (ICC).
Visit 2 (V2) Visit 3 (V3)
Subtest N Mean (SD) N Mean (SD) ICC
VLT-I 74 19.95 (3.81) 74 22.11 (4.07) 0.75
WMT 74 17.70 (4.18) 74 18.11 (4.18) 0.77
VFT 74 15.09 (4.86) 74 16.03 (5.27) 0.67
VLT-D 74 5.23 (2.14) 74 6.62 (2.06) 0.59
PST 74 9.45 (3.13) 74 9.95 (3.31) 0.82
Total SCIP 74 67.42 (13.74) 74 72.81 (14.17) 0.87
VLT-I = Verbal Learning Test-Immediate; WMT = Working Memory 
Test; VFT = Verbal Fluency Test; VLT-D = Verbal Learning Test-
Delayed; PST = Processing Speed Test; Total SCIP = SCIP total score
Table 4: Mean SCIP scores on the baseline (V1) and one week later (V2).
Baseline (V1) Visit 2 (V2)
Subtest N Mean (SD) N Mean (SD) Significance Cohen d
VLT-I 75 19.41 (4.39) 75 19.91 (3.80) t(74) = 1.074 p = 0.286 0.11
WMT 75 17.25 (3.89) 75 17.73 (4.16) t(74) = 1.558 p = 0.123 0.12
VFT 75 14.43 (5.35) 75 15.16 (4.86) t(74) = 1.766 p = 0.081 0.14
VLT-D 75 5.28 (2.43) 75 5.23 (2.13) t(74) = 0.214 p = 0.831 -0.02
PST 75 9.12 (2.75) 75 9.48 (3.12) t(74) = 1.628 p = 0.108 0.13
Total SCIP 75 65.49 (13.74) 75 67.51 (13.67) t(74) = 2.231 p = 0.029* 0.15
* p < 0.05
VLT-I = Verbal Learning Test-Immediate; WMT = Working Memory Test; VFT = Verbal Fluency Test; VLT-D = Verbal Learning Test-Delayed; PST 
= Processing Speed Test; Total SCIP = SCIP total scorePage 6 of 10
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The present results offer support for the feasibility, relia-
bility, and validity of the SCIP as a tool for screening cog-
nitive impairment in bipolar disorders, but some
limitations should be taken into account. A major limita-
tion of the present study refers to the sample size, which
is in the usual range of this sort of studies and provides a
first step towards future investigations of the clinical
applications of this tool, but does not allow more sophis-
ticated statistical subanalysis. Additional data will be
required to confirm the value of the scale in larger clinical
samples.
Another potential weakness relates to the election of the
neuropsychological battery. It should be taken into
account that any effort to validate the SCIP with a gold
standard battery will be limited by the validity, reliability,
and adequacy of the battery.
The SCIP is missing coverage of several potentially impor-
tant cognitive domains that are likely relevant to bipolar
disorder, including measurement of executive function
and nonverbal skills. Supplemental tests will be required
in situations where these skills are a priority. However, we
are also investigating supplemental scoring strategies,
including errors of intrusion and perseverations on the
verbal fluency and verbal learning subtests of the SCIP;
these additional scores may offer valuable measures of
frontal lobe functions that should correlate with executive
and problem solving skills.
Another priority of our future research will be trying to
make a link between individual measures on the SCIP and
corresponding individual measures on the larger neu-
ropsychological battery, in order to explore if the SCIP
subscale scores provide valid measures of their underlying
cognitive domains in bipolar disorder.
The SCIP seems to work properly when it is administered
by psychiatrists who have participated in a relatively brief
training exercise. In future investigations it would be use-
ful to train and evaluate other mental health care profes-
sionals, including nurses, occupational therapists, and
social workers, all of whom are likely equipped with the
skills necessary for a reliable and valid implementation of
this relatively simple standardized assessment instrument.
The SCIP will not replace the diagnostic value of a full
neuropsychological examination, but it will offer a rapid
inexpensive mechanism for screening cases with a lower
probability of significant impairments. In future investi-
gations it would be useful to evaluate the relative sensitiv-
ity and specificity of the SCIP against structural and
functional in vivo neuroimaging evidence of cerebral
pathology in psychiatric and neurological disorders. There
is also fairly broad agreement that cognitive limitations
are related to the educational, occupational, and social
limitations that result from bipolar disorders, and it
would be useful to assess the prognostic value of the SCIP
to psychosocial outcome in future prospective investiga-
tions. It would be also interesting to explore SCIP scores
in patients with bipolar disorder compared to other psy-
chiatric disorders; in this sense preliminary results com-
paring bipolar and schizophrenic samples have shown
slight differences with the bipolar patients exceeding the
performance of the schizophrenic patients on all five SCIP
subtests, but with low d effect sizes ranging from d = 0.00
for PST to 0.30 for VLT-D.
Table 5: Correlations between SCIP subtests.
Subtest VLT-I WMT VFT VLT-D PST
VLT-I - 0.38* 0.43* 0.68* 0.18
WMT - 0.44* 0.41* 0.36*
VFT - 0.47* 0.36*
VLT-D - 0.24
PST -
* p < 0.01
VLT-I = Verbal Learning Test-Immediate; WMT = Working Memory 
Test; VFT = Verbal Fluency Test; VLT-D = Verbal Learning Test-
Delayed; PST = Processing Speed Test; Total SCIP = SCIP total score
Table 6: Mean SCIP scores on the baseline visit (V1).
Patients Controls
Subtest N Mean (SD) Min. – Max. N Mean (SD) Min. – Max. Cohen d
VLT-I 76 19.39 (4.36) 9 – 28 45 21.84 (3.74) 14 – 29 0.59
WMT 76 17.29 (3.88) 8 – 24 45 19.58 (3.17) 12 – 24 0.63
VFT 76 14.42 (5.32) 4 – 31 45 19.73 (5.71) 6 – 32 0.97
VLT-D 76 5.26 (2.42) 0 – 10 45 6.69 (1.87) 2 – 10 0.64
PST 76 9.11 (2.73) 2 – 14 45 12.49 (2.72) 5 – 18 1.24
Total SCIP 76 65.47 (13.57) 27 – 93 45 80.33 (11.06) 40 – 101 1.16
VLT-I = Verbal Learning Test-Immediate; WMT = Working Memory Test; VFT = Verbal Fluency Test; VLT-D = Verbal Learning Test-Delayed; PST 
= Processing Speed Test; Total SCIP = SCIP total scorePage 7 of 10
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Finally, the brevity of the SCIP underscores its potential value
to clinical trials with bipolar disorders directed toward an
improvement in cognitive skills that may mitigate an
improvement in functional outcome. The current investiga-
tion supported the use of alternate forms to reduce practice
effects, potentially increasing sensitivity to treatment-related
changes, but the sensitivity of the SCIP to pharmacothera-
peutic interventions has yet to be confirmed.
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